EA201991074A1 - Ингибиторы magl - Google Patents
Ингибиторы maglInfo
- Publication number
- EA201991074A1 EA201991074A1 EA201991074A EA201991074A EA201991074A1 EA 201991074 A1 EA201991074 A1 EA 201991074A1 EA 201991074 A EA201991074 A EA 201991074A EA 201991074 A EA201991074 A EA 201991074A EA 201991074 A1 EA201991074 A1 EA 201991074A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- magl inhibitors
- useful
- magl
- compositions provided
- Prior art date
Links
- 102100029814 Monoglyceride lipase Human genes 0.000 title abstract 2
- 101710116393 Monoglyceride lipase Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- CWPIBZMCMRNFHK-UHFFFAOYSA-N piperazin-1-ium;carbamate Chemical class NC(O)=O.C1CNCCN1 CWPIBZMCMRNFHK-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
В документе представлены карбаматы пиперазина и фармацевтические композиции, содержащие указанные соединения. Предусмотренные соединения и композиции применимы в качестве модуляторов MAGL. Кроме того, предусмотренные соединения и композиции применимы для лечения боли.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662423095P | 2016-11-16 | 2016-11-16 | |
PCT/US2017/061867 WO2018093946A1 (en) | 2016-11-16 | 2017-11-15 | Magl inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201991074A1 true EA201991074A1 (ru) | 2019-12-30 |
Family
ID=62107273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201991074A EA201991074A1 (ru) | 2016-11-16 | 2017-11-15 | Ингибиторы magl |
Country Status (27)
Country | Link |
---|---|
US (1) | US9981930B1 (ru) |
EP (1) | EP3541822B1 (ru) |
JP (1) | JP6987859B2 (ru) |
KR (1) | KR20190077087A (ru) |
CN (1) | CN110248947B (ru) |
AR (1) | AR110088A1 (ru) |
AU (1) | AU2017361250A1 (ru) |
BR (1) | BR112019009991A2 (ru) |
CA (1) | CA3043612A1 (ru) |
CL (1) | CL2019001335A1 (ru) |
CO (1) | CO2019005038A2 (ru) |
CR (1) | CR20190243A (ru) |
DO (1) | DOP2019000121A (ru) |
EA (1) | EA201991074A1 (ru) |
EC (1) | ECSP19035377A (ru) |
ES (1) | ES2908632T3 (ru) |
IL (1) | IL266550A (ru) |
JO (1) | JOP20190105A1 (ru) |
MA (1) | MA46860A (ru) |
MX (1) | MX2019005771A (ru) |
NI (1) | NI201900050A (ru) |
PE (1) | PE20191146A1 (ru) |
PH (1) | PH12019501102A1 (ru) |
RU (1) | RU2019116514A (ru) |
TN (1) | TN2019000150A1 (ru) |
TW (1) | TW201831458A (ru) |
WO (1) | WO2018093946A1 (ru) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101653473B1 (ko) | 2012-01-06 | 2016-09-01 | 어바이드 테라퓨틱스, 인크. | 카르바메이트 화합물 및 그의 제조 및 이용 방법 |
WO2016183097A1 (en) | 2015-05-11 | 2016-11-17 | Abide Therapeutics, Inc. | Methods of treating inflammation or neuropathic pain |
ES2892952T3 (es) | 2016-09-19 | 2022-02-07 | H Lundbeck As | Carbamatos de piperazina como moduladores del MAGL y/o ABHD6 y su uso |
JOP20190107A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
JOP20190108B1 (ar) | 2016-11-16 | 2023-09-17 | H Lundbeck As | تركيبات صيدلانية |
MA46866B1 (fr) | 2016-11-16 | 2021-11-30 | H Lundbeck As | Une forme cristalline d'un inhibiteur de magl |
JOP20190106A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
BR112020004101A2 (pt) | 2017-08-29 | 2020-09-24 | Lundbeck La Jolla Research Center, Inc. | compostos de espirociclo e métodos para produzir e usar os mesmos |
CU20200037A7 (es) * | 2017-11-02 | 2021-03-11 | Aicuris Gmbh & Co Kg | Derivados de indol-2-carboxamidas sustituidos con amino-tiazol activos contra el virus de la hepatitis b (vhb) |
SG11202011228TA (en) | 2018-05-15 | 2020-12-30 | Lundbeck La Jolla Research Center Inc | Magl inhibitors |
AU2021259496A1 (en) | 2020-04-21 | 2022-11-10 | H. Lundbeck A/S | Synthesis of a monoacylglycerol lipase inhibitor |
TW202229255A (zh) | 2020-11-13 | 2022-08-01 | 丹麥商H 朗德貝克公司 | Magl抑制劑 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1593586A (ru) | 1967-10-17 | 1970-06-01 | ||
JPS6183073A (ja) | 1984-10-01 | 1986-04-26 | Oki Electric Ind Co Ltd | 印字装置の用紙送り方法 |
WO1989011794A1 (en) | 1988-06-07 | 1989-12-14 | Rikagaku Kenkyusho | Plant growth inhibitor |
WO1993011097A1 (en) | 1991-11-27 | 1993-06-10 | E.I. Du Pont De Nemours And Company | Herbicidal acylated amino-(phenyl- or pyridinyl- or thienyl-)-phenyl derivatives |
JPH09506920A (ja) | 1993-12-22 | 1997-07-08 | シエル・インターナシヨナル・リサーチ・マートスハツペイ・ベー・ヴエー | カルバメートの製造法 |
JP2000500448A (ja) | 1995-11-15 | 2000-01-18 | ゼネカ リミテッド | 除草性置換ピラゾール化合物 |
WO1998000408A1 (en) | 1996-07-02 | 1998-01-08 | Novartis Ag | N-phenylimino heterocyclic derivatives and their use as herbicides |
RU2167150C2 (ru) | 1998-03-25 | 2001-05-20 | Фокин Александр Васильевич | Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью |
JP2003511045A (ja) | 1999-10-04 | 2003-03-25 | ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュー ジャージー | Rna結合化合物の同定方法 |
EP1201298A1 (en) | 2000-10-24 | 2002-05-02 | Urea Casale S.A. | Carbamate condensation unit |
DE10348022A1 (de) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
FR2864080B1 (fr) | 2003-12-23 | 2006-02-03 | Sanofi Synthelabo | Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique |
WO2005063698A1 (en) | 2003-12-31 | 2005-07-14 | Council Of Scientific & Industrial Research | Process for preparing carbamates |
BRPI0507499A (pt) | 2004-02-18 | 2007-07-24 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável ou hidrato dos mesmos, composição farmacêutica, uso do composto, e, métodos para tratar distúrbios mediados por mglur 5 e para inibir a ativação de receptores de mglur 5 |
MXPA06011540A (es) * | 2004-04-07 | 2007-01-26 | Millennium Pharm Inc | Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias. |
JP2008521768A (ja) | 2004-12-23 | 2008-06-26 | エフ.ホフマン−ラ ロシュ アーゲー | ヘテロ環式カルバミン酸誘導体、それらの製造及び医薬品としての使用 |
WO2006074025A1 (en) | 2004-12-30 | 2006-07-13 | Janssen Pharmaceutica N.V. | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase |
JP2009523729A (ja) | 2006-01-13 | 2009-06-25 | ピーティーシー セラピューティクス,インコーポレーテッド | C型肝炎の治療方法 |
EP1987037A2 (en) | 2006-02-23 | 2008-11-05 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
AR064491A1 (es) | 2006-12-22 | 2009-04-08 | Astex Therapeutics Ltd | Derivados de imidazo[1, 2-a]pirimidina, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por las quinasas fgfr. |
US7795457B2 (en) | 2007-02-26 | 2010-09-14 | Kosan Biosciences Incorporated | Carbamate compounds |
JP2008239616A (ja) * | 2007-02-28 | 2008-10-09 | Iyaku Bunshi Sekkei Kenkyusho:Kk | Hdl上昇剤 |
US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
CA2730610A1 (en) | 2008-07-16 | 2010-01-21 | Schering Corporation | Bicyclic heterocycle derivatives and their use as gpcr modulators |
US8772318B2 (en) | 2008-11-14 | 2014-07-08 | The Scripps Research Institute | Methods and compositions related to targeting monoacylglycerol lipase |
KR20110131302A (ko) | 2009-03-23 | 2011-12-06 | 엠에스디 가부시키가이샤 | 오로라 a 선택적 억제 작용을 갖는 신규한 아미노피리딘 유도체 |
UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
BR112012010471B1 (pt) | 2009-11-03 | 2020-10-20 | Bayer Materialscience Ag | formulação de fotopolímero compreendendo fluorouretanos e processo para exposição de mídia holográfica |
FR2960875B1 (fr) | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
KR101653473B1 (ko) * | 2012-01-06 | 2016-09-01 | 어바이드 테라퓨틱스, 인크. | 카르바메이트 화합물 및 그의 제조 및 이용 방법 |
SG10201602862RA (en) | 2012-01-06 | 2016-05-30 | Agios Pharmaceuticals Inc | Therapeutically Active Compounds And Their Methods Of Use |
MX2014011134A (es) | 2012-03-19 | 2014-12-10 | Abide Therapeutics Inc | Compuestos de carbamato y preparacion y uso de los mismos. |
US9551036B2 (en) | 2013-02-25 | 2017-01-24 | Whitehead Institute For Biomedical Research | Metabolic gene mesenchymal signatures and uses thereof |
MX2015017961A (es) | 2013-07-03 | 2016-10-14 | Abide Therapeutics Inc | Compuestos orgánicos pirrolo-pirrol carbamato y relacionados, composiciones farmacéuticas y usos médicos de los mismos. |
US9771341B2 (en) | 2015-03-18 | 2017-09-26 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
WO2016183097A1 (en) * | 2015-05-11 | 2016-11-17 | Abide Therapeutics, Inc. | Methods of treating inflammation or neuropathic pain |
US10463753B2 (en) * | 2016-02-19 | 2019-11-05 | Lundbeck La Jolla Research Center, Inc. | Radiolabeled monoacylglycerol lipase occupancy probe |
US10030020B2 (en) * | 2016-05-12 | 2018-07-24 | Abide Therapeutics, Inc. | Spirocycle compounds and methods of making and using same |
JOP20190107A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
JOP20190267A1 (ar) * | 2017-05-23 | 2019-11-18 | Lundbeck La Jolla Research Center Inc | مثبطات بيرازول magl |
-
2017
- 2017-06-16 JO JOP/2019/0105A patent/JOP20190105A1/ar unknown
- 2017-11-15 BR BR112019009991A patent/BR112019009991A2/pt not_active Application Discontinuation
- 2017-11-15 US US15/814,318 patent/US9981930B1/en active Active
- 2017-11-15 JP JP2019523589A patent/JP6987859B2/ja active Active
- 2017-11-15 WO PCT/US2017/061867 patent/WO2018093946A1/en active Application Filing
- 2017-11-15 RU RU2019116514A patent/RU2019116514A/ru not_active Application Discontinuation
- 2017-11-15 AR ARP170103183A patent/AR110088A1/es unknown
- 2017-11-15 ES ES17871883T patent/ES2908632T3/es active Active
- 2017-11-15 KR KR1020197016859A patent/KR20190077087A/ko unknown
- 2017-11-15 TN TNP/2019/000150A patent/TN2019000150A1/en unknown
- 2017-11-15 MA MA046860A patent/MA46860A/fr unknown
- 2017-11-15 EP EP17871883.9A patent/EP3541822B1/en active Active
- 2017-11-15 PE PE2019001015A patent/PE20191146A1/es unknown
- 2017-11-15 CN CN201780083635.4A patent/CN110248947B/zh active Active
- 2017-11-15 MX MX2019005771A patent/MX2019005771A/es unknown
- 2017-11-15 EA EA201991074A patent/EA201991074A1/ru unknown
- 2017-11-15 CA CA3043612A patent/CA3043612A1/en not_active Abandoned
- 2017-11-15 AU AU2017361250A patent/AU2017361250A1/en not_active Abandoned
- 2017-11-15 CR CR20190243A patent/CR20190243A/es unknown
- 2017-11-16 TW TW106139750A patent/TW201831458A/zh unknown
-
2019
- 2019-05-12 IL IL266550A patent/IL266550A/en unknown
- 2019-05-16 CO CONC2019/0005038A patent/CO2019005038A2/es unknown
- 2019-05-16 DO DO2019000121A patent/DOP2019000121A/es unknown
- 2019-05-16 NI NI201900050A patent/NI201900050A/es unknown
- 2019-05-16 CL CL2019001335A patent/CL2019001335A1/es unknown
- 2019-05-16 PH PH12019501102A patent/PH12019501102A1/en unknown
- 2019-05-17 EC ECSENADI201935377A patent/ECSP19035377A/es unknown
Also Published As
Publication number | Publication date |
---|---|
ES2908632T3 (es) | 2022-05-03 |
IL266550A (en) | 2019-07-31 |
MX2019005771A (es) | 2019-12-05 |
TN2019000150A1 (en) | 2020-10-05 |
NI201900050A (es) | 2019-10-30 |
WO2018093946A1 (en) | 2018-05-24 |
CO2019005038A2 (es) | 2019-05-31 |
US20180134675A1 (en) | 2018-05-17 |
MA46860A (fr) | 2019-09-25 |
EP3541822A4 (en) | 2020-04-29 |
CN110248947A (zh) | 2019-09-17 |
CA3043612A1 (en) | 2018-05-24 |
US9981930B1 (en) | 2018-05-29 |
RU2019116514A (ru) | 2020-12-17 |
JP6987859B2 (ja) | 2022-01-05 |
CN110248947B (zh) | 2022-04-01 |
BR112019009991A2 (pt) | 2019-08-27 |
KR20190077087A (ko) | 2019-07-02 |
EP3541822A1 (en) | 2019-09-25 |
CR20190243A (es) | 2019-06-26 |
CL2019001335A1 (es) | 2019-10-04 |
AU2017361250A1 (en) | 2019-05-30 |
PH12019501102A1 (en) | 2019-08-19 |
DOP2019000121A (es) | 2019-09-30 |
JP2020502047A (ja) | 2020-01-23 |
PE20191146A1 (es) | 2019-09-02 |
EP3541822B1 (en) | 2022-01-19 |
TW201831458A (zh) | 2018-09-01 |
JOP20190105A1 (ar) | 2019-05-09 |
AR110088A1 (es) | 2019-02-20 |
ECSP19035377A (es) | 2019-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201991073A1 (ru) | Ингибиторы magl | |
EA201991074A1 (ru) | Ингибиторы magl | |
EA202092586A1 (ru) | Ингибиторы magl | |
MX2017011997A (es) | Carbamatos de piperacina y metodos de preparacion y uso. | |
EA201991029A1 (ru) | Ингибиторы magl | |
EA201890204A1 (ru) | Антибактериальные соединения | |
EA201990043A1 (ru) | Антибактериальные соединения | |
EA201891203A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
EA201990044A1 (ru) | Гетероциклические соединения в качестве антибактериальных средств | |
EA202090296A1 (ru) | Спироциклические соединения и способы их получения и применения | |
EA201890754A1 (ru) | Соединения и способы их применения | |
EA201691845A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
PH12019502646A1 (en) | Pyrazole magl inhibitors | |
EA201691844A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
CL2015002897A1 (es) | Inhibidores de bace1 | |
EA201591925A1 (ru) | Терапевтические композиции и их применение | |
EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
EA202090312A1 (ru) | Спироциклические соединения и способы их получения и применения | |
BR112019024566A2 (pt) | inibidores de pirazol magl | |
EA201692008A1 (ru) | Замещенные сконденсированные гетероциклы в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных нарушений | |
EA201790156A1 (ru) | Азетидинилоксифенилпирролидиновые соединения | |
EA201590932A1 (ru) | Композиции, содержащие вортиоксетин и донепезил | |
EA201991898A1 (ru) | Двойные ингибиторы magl и faah | |
EA201691896A1 (ru) | Соединения и способы их применения | |
EA201892376A1 (ru) | Комбинированный состав трех противовирусных соединений |